PMDA drug package insert
ラピアクタ点滴静注液バッグ300mg
PMDA Prescription drug · 塩野義製薬株式会社 · package insert Sep 5, 2025
Key facts
| Brand names | ラピアクタ点滴静注液バッグ300mg, ラピアクタ点滴静注液バイアル150mg |
|---|---|
| Nonproprietary names | ペラミビル水和物 |
| Companies | 製造販売元／塩野義製薬株式会社, 提携／BIOCRYST PHARMACEUTICALS, INC. |
| Product type | Prescription drug |
| Therapeutic category | 抗インフルエンザウイルス剤 |
| Therapeutic category codes | 87625 |
| YJ codes | 6250405A2039, 6250405A1032 |
| Approval numbers | 22300AMX01152000, 22300AMX01151000 |
| Package insert edition | 第3版 |
| Package insert date | Sep 5, 2025 |
| PMDA document key | 340018_6250405A1032_1 |
| PMDA company code | 340018 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: